Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Real-World Comparison of BCL2 Inhibitor and BTK Inhibitor Therapy in the Front-Line Treatment of CLL Including Patients with Del(17p)/TP53 Mutation

Daniel A. Ermann, Victoria A. Vardell, Allison M. Bock, Joshua J. Horns, Harsh R. Shah, Lindsey Fitzgerald, Boyu Hu, Adam S Kittai, Deborah M. Stephens

Blood (2024) 144 (Supplement 1): 1864.

https://doi.org/10.1182/blood-2024-204134

Published: 2024

Journal Articles

Feasibility of Discontinuation of Bruton's Tyrosine Kinase Inhibitors in Patients with Chronic Lymphocytic Leukemia: A Patient Survey

Deborah M. Stephens, Chris Stewart, Liza Avruch, Catherine C Coombs, Alexey Danilov, Brian T. Hill, Mazyar Shadman, Alina S. Gerrie, Christopher E. Jensen, Marc Hoffmann, Allison M. Winter, Daniel A. Ermann, Paul M Barr, Susan M. O'Brien, Brian Koffman, John C. Byrd

Blood (2024) 144 (Supplement 1): 7743.

https://doi.org/10.1182/blood-2024-193298

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

Blood (2024) 144 (Supplement 1): 887.

https://doi.org/10.1182/blood-2024-200339

Published: 2024

Journal Articles

A Real-World Comparative Analysis of Hypertension and Time to Treatment Failure with Acalabrutinib Vs Ibrutinib in Treatment-Naïve Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Daniel A. Ermann, George Dranitsaris, Sibel Blau, Aaron Peevyhouse, Heather Neuhalfen, Alan SM Yong, Tina K. Wahlstrom, Samantha L. Thompson, Anna Teschemaker, Vikram Shetty, Mayur S. Narkhede

Blood (2024) 144 (Supplement 1): 6367.

https://doi.org/10.1182/blood-2024-210396

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004

Blood (2024) 144 (Supplement 1): 4633.

https://doi.org/10.1182/blood-2024-200840

Published: 2024

Journal Articles

Real World Outcomes of Black Americans with Mantle Cell Lymphoma

Victoria A. Vardell, Boyu Hu, Lindsey Fitzgerald, Harsh Shah, Allison M. Bock, Deborah M. Stephens, Daniel A. Ermann

Blood (2023) 142 (Supplement 1): 4412.

https://doi.org/10.1182/blood-2023-190719

Published: 2023

Journal Articles

Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy

Steven M. Bair, Mayur Narkhede, Zachary AK Frosch, Elise A. Chong, Daniel A. Ermann, Iris Isufi, Farrukh T. Awan, Julio C Chavez, Grace N Bosma, Diana Abbott

Blood (2023) 142 (Supplement 1): 68.

https://doi.org/10.1182/blood-2023-187113

Published: 2023

Journal Articles

Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy

Blood (2023) 142 (Supplement 1): 308.

https://doi.org/10.1182/blood-2023-183001

Published: 2023

Journal Articles

Trends in Survival Outcomes for Mantle Cell Lymphoma in the Era of Novel Therapies

Daniel A. Ermann, Victoria A. Vardell, Lindsey Fitzgerald, Harsh Shah, Allison M. Bock, Deborah M. Stephens, Boyu Hu

Blood (2023) 142 (Supplement 1): 1669.

https://doi.org/10.1182/blood-2023-190383

Published: 2023

Journal Articles

Survival Outcomes of Rural Patients with Mantle Cell Lymphoma

Zach Rubnitz, Victoria A. Vardell, Lindsey Fitzgerald, Allison M. Bock, Harsh Shah, Boyu Hu, Deborah M. Stephens, Daniel A. Ermann

Blood (2023) 142 (Supplement 1): 6169.

https://doi.org/10.1182/blood-2023-189285

Published: 2023

Journal Articles

Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Blood (2022) 140 (Supplement 1): 9390–9392.

https://doi.org/10.1182/blood-2022-159001

Published: 2022

Journal Articles

Treatment and Overall Survival Outcomes of Patients with B-Cell Prolymphocytic Leukemia

Daniel A. Ermann, Victoria A. Vardell, Lindsey A. Fitzgerald, Harsh Shah, Boyu Hu, Deborah M. Stephens

Blood (2022) 140 (Supplement 1): 6668–6669.

https://doi.org/10.1182/blood-2022-170666

Published: 2022

Journal Articles

Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort

Blood (2022) 140 (Supplement 1): 10391–10393.

https://doi.org/10.1182/blood-2022-159725

Published: 2022

Journal Articles

T-Cell Prolymphocytic Leukemia: Trends in Overall Survival Demonstrate Marginal Improvement over Time and Minimal Benefit with Currently Available Treatments

Victoria A. Vardell, Daniel A. Ermann, Harsh Shah, Lindsey A. Fitzgerald, Boyu Hu, Deborah M. Stephens

Blood (2022) 140 (Supplement 1): 1085–1086.

https://doi.org/10.1182/blood-2022-169918

Published: 2022

Journal Articles

Survival Disparities Among People with HIV and Diffuse Large B-Cell Lymphoma in the Era of Novel Antiretroviral Therapy

Daniel A. Ermann, Victoria A. Vardell, Manasa Velagapudi, Greer Burkholder, Lindsey A. Fitzgerald, Mayur Narkhede, Harsh Shah, Lauren Shea, Adam Spivak, Deborah M. Stephens, Boyu Hu, Gaurav Goyal

Blood (2022) 140 (Supplement 1): 1076–1078.

https://doi.org/10.1182/blood-2022-169930

Published: 2022

Journal Articles

Treatment Outcomes of Consolidative Radiation in Extranodal Early-Stage Diffuse Large B-Cell Lymphoma

Daniel A. Ermann, Victoria A. Vardell, Harsh Shah, Randa Tao, David K. Gaffney, Deborah M. Stephens, Boyu Hu

Blood (2021) 138 (Supplement 1): 49.

https://doi.org/10.1182/blood-2021-153197

Published: 2021

Journal Articles

Multiple Myeloma Patients Treated at Academic Centers Have Improved Survival Outcomes

Victoria A. Vardell, Daniel A. Ermann, Srinivas K. Tantravahi, Brian McClune, Mary Nicole Steinbach, Ghulam Rehman Mohyuddin, Amandeep Godara, Douglas W. Sborov

Blood (2021) 138 (Supplement 1): 1971.

https://doi.org/10.1182/blood-2021-151899

Published: 2021

Journal Articles

Angioimmunoblastic T-Cell Lymphoma: Patient Characteristics and Survival Outcomes

Daniel A. Ermann, MD, Victoria A. Vardell, MD, Peter T. Silberstein, MD

Blood (2019) 134 (Supplement_1): 2194.

https://doi.org/10.1182/blood-2019-132077

Published: 2019

Journal Articles

Academic Centers Are Associated with Improved Survival Outcomes in High Risk Diffuse Large B-Cell Lymphoma Patients

Daniel A. Ermann, MD, Victoria Vardell Noble, Avyakta Kallam, MBBS, James O. Armitage, MD

Blood (2018) 132 (Supplement 1): 4747.

https://doi.org/10.1182/blood-2018-99-115578

Published: 2018

Journal Articles

Primary Thyroid Lymphoma: An Analysis of the National Cancer Database

Victoria Vardell Noble, Daniel A. Ermann, MD, Peter T. Silberstein, MD

Blood (2018) 132 (Supplement 1): 2988.

https://doi.org/10.1182/blood-2018-99-120145

Published: 2018

NARROW

Real-World Comparison of BCL2 Inhibitor and BTK Inhibitor Therapy in the Front-Line Treatment of CLL Including Patients with Del(17p)/TP53 Mutation

Feasibility of Discontinuation of Bruton's Tyrosine Kinase Inhibitors in Patients with Chronic Lymphocytic Leukemia: A Patient Survey

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

A Real-World Comparative Analysis of Hypertension and Time to Treatment Failure with Acalabrutinib Vs Ibrutinib in Treatment-Naïve Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004

Real World Outcomes of Black Americans with Mantle Cell Lymphoma

Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy

Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy

Trends in Survival Outcomes for Mantle Cell Lymphoma in the Era of Novel Therapies

Survival Outcomes of Rural Patients with Mantle Cell Lymphoma

Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Treatment and Overall Survival Outcomes of Patients with B-Cell Prolymphocytic Leukemia

Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort

T-Cell Prolymphocytic Leukemia: Trends in Overall Survival Demonstrate Marginal Improvement over Time and Minimal Benefit with Currently Available Treatments

Survival Disparities Among People with HIV and Diffuse Large B-Cell Lymphoma in the Era of Novel Antiretroviral Therapy

Treatment Outcomes of Consolidative Radiation in Extranodal Early-Stage Diffuse Large B-Cell Lymphoma

Multiple Myeloma Patients Treated at Academic Centers Have Improved Survival Outcomes

Angioimmunoblastic T-Cell Lymphoma: Patient Characteristics and Survival Outcomes

Academic Centers Are Associated with Improved Survival Outcomes in High Risk Diffuse Large B-Cell Lymphoma Patients

Primary Thyroid Lymphoma: An Analysis of the National Cancer Database

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only